Cytena GmbH, part of the BICO Group, is a leading life science company specializing in the development, manufacturing, and marketing of innovative single-cell isolation and handling technologies. Their solutions are crucial for applications such as cell line development, single-cell genomics, and proteomics, enabling researchers and scientists to advance drug discovery, personalized medicine, and bioprocessing. Cytena's instruments, like the c.sight™, f.sight™, and UP.SIGHT™, are renowned for their precision, speed, and gentle cell handling, ensuring cell viability and integrity. Acquired by BICO (formerly CELLINK) in 2019, Cytena continues to innovate within the bioconvergence landscape.
Serves as the primary center for research and development, manufacturing, global sales operations, and administrative functions for Cytena's single-cell technology portfolio.
Modern laboratory and production facilities equipped for advanced biotechnology research, precision engineering, and instrument assembly.
A dynamic and innovative environment driven by scientific excellence and engineering precision. Fosters collaboration, problem-solving, and a commitment to quality, reflecting both its German engineering heritage and its role within the forward-looking BICO group.
The Freiburg HQ is pivotal for Cytena's technological advancements in single-cell dispensing and is a key innovation and manufacturing site within the BICO group, contributing significantly to the field of bioconvergence.
Cytena, as part of BICO, has a significant global footprint. Its operations are primarily centered in Europe (Germany HQ) and North America (USA office), with a growing presence in Asia-Pacific (China office). Globally, Cytena supports functions including R&D, manufacturing, direct sales, distribution partnerships, customer service, technical and application support. This international network allows Cytena to serve a diverse customer base in academia, pharmaceutical, and biotechnology industries worldwide.
Georges-Köhler-Allee 302
Freiburg im Breisgau
Baden-Württemberg
Germany
Address: c/o BICO, 100 Forge, 480 Arsenal St, Watertown, MA 02472, USA
To strengthen Cytena's presence in the key North American market, providing localized customer support and fostering collaborations to drive adoption of its single-cell technologies.
Address: c/o BICO China, Room 302, Building 2, Lane 588, Zixing Road, Minhang District, Shanghai, China
To expand market reach and provide tailored support to customers in the APAC region, adapting to local research needs and industry trends.
Address: c/o BICO Group HQ, Arvid Wallgrens Backe 20, 413 46 Gothenburg, Sweden
Integration with parent company operations, leveraging group synergies for R&D, market strategy, and global outreach.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, CYTENA' leadership includes:
CYTENA has been backed by several prominent investors over the years, including:
No specific high-profile Cytena executive hires or exits have been publicly announced in the last 12 months. Changes may occur within the broader BICO group that could influence subsidiary leadership. Cytena's core leadership team appears stable.
Discover the tools CYTENA uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cytena likely utilizes common corporate email formats. Based on industry standards and practices within the BICO group, the most probable formats would involve combinations of first name, last name, or initials.
firstname.lastname@cytena.com or f.lastname@cytena.com
Format
john.doe@cytena.com
Example
80%
Success rate
BICO Group • May 7, 2024
In BICO's Q1 2024 report, the Single-Cell Technologies division, prominently featuring Cytena, showed continued strong demand for consumables. The report noted a slight decline in instrument sales due to cautious capital expenditure but highlighted Cytena's overall positive contribution and strategic importance within the group....more
Cytena News • November 15, 2023
Cytena announced its participation as an associate partner in the ENABLE (European Network for the Advancement of Lytic Bacteriophage Therapy) Consortium. This collaboration aims to advance phage therapy, with Cytena contributing its expertise in single-cell isolation to isolate and characterize bacteriophages....more
Cytena News • August 25, 2022
CYTENA and CELLINK announced a collaboration with the Comprehensive Cancer Center at Wake Forest Baptist, one of only 53 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the United States. This collaboration aims to accelerate cancer research by providing advanced single-cell isolation and bioprinting technologies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including CYTENA, are just a search away.